首页>
外国专利>
QUINOLINE-UREA DERIVATIVES FOR THE TREATMENT OF WITHDRAWAL SYNDROME AND WITHDRAWAL-INDUCED BRAIN DAMAGE
QUINOLINE-UREA DERIVATIVES FOR THE TREATMENT OF WITHDRAWAL SYNDROME AND WITHDRAWAL-INDUCED BRAIN DAMAGE
展开▼
机译:喹啉脲衍生物治疗戒断综合征和戒断引起的脑损伤
展开▼
页面导航
摘要
著录项
相似文献
摘要
Compounds, compositions and method for ameliorating alcohol or drug dependency withdrawal syndromes and withdrawal-induced brain damage are disclosed. In particular, a series of N-substituted-4-ureido-5,7-dihalo-2-carboxy quinoline compounds are disclosed having combined properties as antagonists of voltage-sensitive sodium channels (VSNaC) and as selective competitive antagonists at the strychnine-intensive glycine site of N-methyl-D-aspartate (NMDA) receptors. The disclosed compounds prevent or reduce the signs and symptoms of neurohyperexcitability and particularly the neurohyperexcitability associated with withdrawal syndrome manifested by patients upon withdrawal from chronic use of dependence inducing agents (e.g, ethanol, barbiturates, opiates etc.). The combined actions of the disclosed compounds on VSNaC and NMDA receptors also impart properties to these compounds that are important in preventing and reducing excitotoxic neurodegeneration and reducing anxiety without the undesirable CNS depressant side-effects of agents hitherto employed for these purposes.
展开▼